Newcastle University

Prof. Ruth Plummer
Clin Prof of Experimental Cancer Med

• Email: ruth.plummer@ncl.ac.uk
• Telephone: +44 (0) 191 246 4414
• Address: Northern Institute for Cancer Research
  Medical School
  University of Newcastle upon Tyne
  NE2 4HH

Selected Publications

• Plummer, E. R.; Ghielmini, M.; Calvert, P. M.; Voi, M.; Renard, J.; Gallant, G.; Gupta, E.; Calvert, A. H.; Sessa, C. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clinical Cancer Research 2002, 8(9), 2788-2797.
• Plummer, E. R.; Watson, A. J.; Boddy, A. V.; Calvert, A. H.; Harris, A. L.; Newell, D. R.; Curtin, N. J.; Middleton, M. R.; Jones, C.; Olsen, A.; Hickson, I.; McHugh, P.; Margison, G. P.; McGown, G.; Thorncroft, M. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clinical Cancer Research 2005, 11(9), 3402-3409.
• Plummer, E. R.; Jackman, A.; Mitchell, F.; Smith, R.; Douglass, E.; Rees, C.; Hughes, A. N.; Beale, P.; Highley, M. S.; Trigo, J.; Gokul, S.; Judson, I.; Calvert, A. H. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clinical Cancer Research 2003, 9(4), 1313-1322.
• Boddy, A. V.; Verrill, M. W.; Calvert, A. H.; Plummer, E. R.; Todd, R.; Sludden, J.; Griffin, M. J.; Robson, L.; Cassidy, J.; Bissett, D.; Bernareggi, A. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clinical Cancer Research 2005, 11(21), 7834-7840.
• Hughes, A. N.; Calvert, P. M.; Azzabi, A.; Plummer, E. R.; Johnson, R.; Rusthoven, J.; Griffin, M. J.; Fishwick, K. A.; Boddy, A. V.; Verrill, M. W.; Calvert, A. H. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2002, 20(16), 3533-3544.
• Plummer, E. R. Inhibition of poly(ADP-ribose) polymerase in cancer. Current Opinion in Pharmacology 2006, 6(4), 364-368.